1,3-Dihydro-pentamethyl-disilazan | 19923-75-2

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 1,3-Dihydro-pentamethyl-disilazan
• 英文别名: N,N-bis(dimethylsilyl)methanamine
• CAS: 19923-75-2
• 化学式: C₅H₁₇NSi₂
• 分子量: 147.368
• InChiKey: YNDNVOKCBWAXLI-UHFFFAOYSA-N

物化性质

• 沸点：
  104.2±9.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.88
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,3-Dihydro-pentamethyl-disilazan 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 生成 1.7-Dihydro-undecamethyl-tetrasilazan
  参考文献：
  名称：

  Andrianov,K.A. et al., Doklady Chemistry, 1967, vol. 176, p. 751 - 754

  摘要：

  DOI：
• 作为产物：
  描述：

  二甲基一氯硅烷 、 甲胺 生成 1,3-Dihydro-pentamethyl-disilazan
  参考文献：
  名称：

  Reaction of 1,3-dihydromethyldisilazanes and 1,3-dihydrotetramethyldisiloxane with allylamines

  摘要：

  DOI：

  10.1007/bf00908439
• 作为试剂：
  描述：

  三乙基氯硅烷 、 benzyl (3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethyl-3-oxospiro[2,4,4a,5,6,6a,6b,7,8,10,12,12a-dodecahydro-1H-naphtho[2,1-a]azulene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-carboxylate 在 1,3-Dihydro-pentamethyl-disilazan 作用下， 以 四氢呋喃 为溶剂， 以78%的产率得到benzyl (3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bR)-3',6',11,12b-tetramethyl-3-triethylsilyloxyspiro[1,2,4a,5,6,6a,6b,7,8,10,12,12a-dodecahydronaphtho[2,1-a]azulene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-carboxylate
  参考文献：
  名称：

  Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)

  摘要：

  Recent evidence suggests that blocking aberrant hedgehog pathway signaling may be a promising therapeutic strategy for the treatment of several types of cancer. Cyclopamine, a plant Veratrum alkaloid, is a natural product antagonist of the hedgehog pathway. In a previous report, a seven-membered D-ring semisynthetic analogue of cyclopamine, IPI-269609 (2), was shown to have greater acid stability and better aqueous solubility compared to cyclopamine. Further modifications of the A-ring system generated three series of analogues with improved potency and/or Solubility. Lead compounds from each series were characterized in vitro and evaluated in vivo for biological activity and pharmacokinetic properties. These studies led to the discovery of IPI-926 (compound 28), a novel semisynthetic cyclopamine analogue with substantially improved pharmaceutical properties and potency and a favorable pharmacokinetic profile relative to cyclopamine and compound 2. As a result, complete tumor regression was observed in a Hh-dependent medulloblastoma allograft model after daily oral administration of 40 mg/kg of compound 28.

  DOI：

  10.1021/jm900305z

文献信息

• Gundersen, Grete; Rankin, David W. H.; Robertson, Heather E., Journal of the Chemical Society, Dalton Transactions, 1985, p. 191 - 198
  作者：Gundersen, Grete、Rankin, David W. H.、Robertson, Heather E.

  DOI：——

  日期：——